Judicial demands for prostate cancer treatment in Brazil: androgen receptor pathway inhibitors are an urgent public health problem
A total of 89% of the 3,136 legal demands sought medication. Androgen inhibitors amounted to 78.8% of all lawsuits, particularly abiraterone. There is a growth tendency in judicialization, with a 30-fold increase over 4 years. The estimated annual financial burden of judicialization on the Brazilian United Public Health System has reached BRL 783 million.
Authors
- R Silva (ORCID: https://orcid.org/0009-0007-5809-0087)
- Sidney Glina (ORCID: https://orcid.org/0000-0002-9053-5046)
- Vanessa Teich (ORCID: https://orcid.org/0000-0002-8539-6037)
- Fernando Korkes (ORCID: https://orcid.org/0000-0003-4261-4345)
- Flávio Tocci Moreira (ORCID: https://orcid.org/0000-0001-6574-3866)
- Luciana Holtz de Camargo Barros (ORCID: https://orcid.org/0000-0003-2184-044X)
- Carlos Henrique Sartorato Pedrotti (ORCID: https://orcid.org/0000-0002-0634-7086)
- Mariana Avelar da Silveira (ORCID: https://orcid.org/0009-0003-7034-9515)
- Carla de Oliveira Ricomini
Institutions
- Hospital Israelita Albert Einstein (BR)
- Instituto de Oncologia do Paraná (BR)
- Faculdade de Medicina do ABC (BR)
Publication Details
- Journal
- Einstein (São Paulo)
- Published
- 2025-01-01
- DOI
- https://doi.org/10.31744/einstein_journal/2025gs1301
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00